2024 Danaher Summit: From Promise to Practice

Joan LaRovere, Virtue Foundation

Moderated by Brad Gray, Danaher

Virtue Foundation's AI-driven platform revolutionizes the matching of volunteer physicians and surgeons with areas of greatest need by using advanced data analytics and machine learning to optimize the allocation of medical expertise in 72 low- and middle-income countries.
 

Daphne Koller, insitro

Moderated by Jose-Carlos Gutiérrez-Ramos, Danaher

insitro is revolutionizing target and drug discovery by integrating multimodal data from human cohorts and cellular models with AI and machine learning to uncover genetic targets for complex diseases. Their approach, grounded in human genetics and focused on metabolic disease, neurodegeneration, and oncology, aims to increase the probability of success and optimize clinical trials by targeting patients who can benefit the most.
 

This panel critically examines the impact of AI in the pharmaceutical industry over the past decade, highlighting both tangible successes like accelerated drug discovery and predictive analytics, as well as notable failures where expectations were not met. Insights from the discussion aim to help stakeholders navigate future AI applications more realistically, focusing on areas with the highest potential for meaningful impact.

Moderated by Murali Venkatasen, Danaher

Panelists:

• Andreas Busch, AbSci
• Steve Crossan, DayHoff Labs
• Najat Khan, Recursion
• Subha Madhavan, Pfizer

This panel of experts explores the practical applications of evolving AI technologies in life sciences, discussing real-world examples and future possibilities. Topics include AI-driven protein modeling, digital pathology, in silico screening and human virtual models, highlighting their impact on drug discovery, diagnostic accuracy, personalized medicine, and the future of clinical trials, while also addressing regulatory considerations and potential challenges.

Moderated by Martin Stumpe, Danaher

Panelists:

• Mark DePristo, BigHat Bio
• Gevorg Grigorian, Generate:Biomedicines
• Emma Lundberg, Stanford University
• Faisal Mahmood, Harvard Medical School

Artificial intelligence has the potential to revolutionize healthcare by enhancing diagnostic accuracy, streamlining treatment processes, and improving patient outcomes. This panel brings together leading experts to explore the barriers to widespread AI adoption in clinical practice and propose strategies for overcoming these challenges.

Moderated by Sadik Kassim, Danaher

Panelists:

• Regina Barzilay, Massachusetts Institute of Technology
• David Dellamonica, AstraZeneca
• Anthony Philippakis, GV
• Philip Tagari, insitro

Predictive AI is revolutionizing clinical trials by improving diversity, overcoming patient recruitment barriers, and enhancing real-time decision-making. Our panelists discuss how AI addresses trial optimization, patient stratification, and early risk prediction, ultimately reducing costs and accelerating timelines.

Moderated by Nicole Selenko-Gebauer, Danaher

Panelists:

• Jeff Elton, ConcertAI
• Ben Liu, Formation Bio
• Ziad Obermeyer, University of California, Berkeley
• Kate Sasser, Tempus

AI's impact extends beyond life sciences and healthcare, and this panel will draw valuable insights from fields like physics, autonomous car development, retail, and even Formula 1 racing. Diverse panelists discuss how advancements in these areas can enhance predictive capabilities, streamline R&D, and drive innovation in life sciences, addressing efficiency, cost reduction, and accelerated discovery and development timelines while inspiring cross-industry collaboration.

Moderated by Vanessa Almendro, Danaher

Panelists:

• Jacomo Corbo, PhysicsX
• Usama Fayyad, Institute for Experimental AI
• Rory Kelleher, NVIDIA
• Shweta Maniar, Google

Presented by Martin Stumpe, Danaher

Expectations for AI to impact business are at an all-time high due to recent advancements in generative AI and Large Language Models, yet real-world results vary significantly across companies and sectors. In healthcare and life sciences, challenges such as messy data, complex workflows, and lengthy regulatory paths hinder progress, but a holistic redesign of workflows and products can unlock AI's transformative potential.

Presented by Jose-Carlos Gutierrez-Ramos, Danaher

Since the Human Genome Project, the way we do science has fundamentally changed. Today, almost all science is "data science," with biology generating massive and complex datasets and computational agents continuing to shift our approach to experimentation and data analysis.